<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593918</url>
  </required_header>
  <id_info>
    <org_study_id>7K08HL071742-05</org_study_id>
    <nct_id>NCT00593918</nct_id>
  </id_info>
  <brief_title>Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children</brief_title>
  <acronym>IIRI</acronym>
  <official_title>Innate Immunity and RSV Infection in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4
      gene to induce varying levels of inflammatory chemokine and cytokine production.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infection with RSV is the most common cause of respiratory tract illnesses (LRIs) in the
      first 3 years of life. There are significant social and health care costs associated with
      RSV-LRIs. More than 3% of US children are hospitalized each year due to RSV and 500 die
      annually. Several longitudinal studies have also suggested that children who have RSV-LRIs
      are at substantially increased risk of developing asthma in the first 3 years after infection
      and bronchial hyperresponsiveness (BHR) many years after the primary infection. Mechanisms
      involved in RSV disease are not well understood. Recent reports suggest that RSV may initiate
      the innate immune response through the pattern recognition receptor, Toll like receptor-4
      (TLR4). In this project we will study the capacity for single nucleotide polymorphisms (SNP)
      in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production. It
      has been suggested that such a mechanism may result in altered immune responses to RSV
      infection and different clinical outcomes. This research has direct application to improving
      our understanding of bronchiolitis in early childhood, particularly those factors that
      influence severity of the disease, and may have implications for possible therapy of patients
      with bronchiolitis in the future.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal Interferon (IFN)-a2</measure>
    <time_frame>1-5 days during acute illness (not after day 5 of illness)</time_frame>
    <description>Interferon a2 was measured from nasal lavage samples by Luminex multiplex assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Detected Nasal Interferon (IL)-2 Cytokine Expression</measure>
    <time_frame>1-5 days during acute illness (not after day 5 of illness)</time_frame>
    <description>IL-2 measured from nasal lavage samples by Luminex multiplex assay</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">91</enrollment>
  <condition>Respiratory Syncytial Virus Infection</condition>
  <arm_group>
    <arm_group_label>Toll-like Receptor 4 -2026/GG Genotype</arm_group_label>
    <description>Toll-like Receptor 4 (TLR4) -2026/GG Genotype of interest hypothesized to be associated with less inflammation during Respiratory Syncytial virus (RSV) infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toll-like Receptor 4 -2026/AG and AA Genotypes</arm_group_label>
    <description>Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during respiratory syncytial virus (RSV) infection</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasal samples Supernatant from Peripheral mononuclear cell stimulation cultures DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children who present with viral upper respiratory infections or bronchiolitis to their
        primary care physician. Upon consent, children willl have cheek samples for genotyping and
        nasal secretion samples to determine RSV infection.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Parental or sibling history of asthma.

          2. Child must be less than 24 months of age.

          3. Presence of viral upper or lower respiratory tract symptoms.

        Exclusion Criteria:

          1. History of recurrent wheezing requiring systemic corticosteroids.

          2. Prior history of lung disease.

          3. Birth &lt; 36 weeks gestation.

          4. Immunodeficiency

          5. Treatment with ribavirin, systemic or inhaled corticosteroids during the RSV
             infection.

          6. Congenital heart disease.

          7. No history of parental or sibling asthma.

          8. Less than 48 hour or more than 5 day duration of viral URI symptoms since the peak
             symptoms from RSV would be expected to occur from 2-5 days into course of infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa W. Guilbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-9988</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <results_first_submitted>June 19, 2009</results_first_submitted>
  <results_first_submitted_qc>April 13, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2010</results_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RSV, asthma, innate immunity, gene, cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study details planned during the first 4 months of the study. Recruitment period began during the RSV seasons from November to May each year from 2003-2008 in medical clinics.</recruitment_details>
      <pre_assignment_details>Patients were enrolled if they met the enrollment criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Toll-like Receptor 4 GG Genotype</title>
          <description>Toll-like Receptor 4 (TLR4) -2026/GG gentoype hypothesized to be associated with less inflammation during Respiratory syncytial virus (RSV) infection</description>
        </group>
        <group group_id="P2">
          <title>Toll-like Receptor 4 AG/AA Genotypes</title>
          <description>Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during Respiratory syncytial virus (RSV) infection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17">Number of children with Toll-like Receptor 4 (TLR4) -2026/GG Genotype</participants>
                <participants group_id="P2" count="74">Number of children with Toll-like Receptor 4 (TLR4) -2026/AG and AA genotypes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12">Some children did not come in for the blood draw at visit 2</participants>
                <participants group_id="P2" count="50">Some children did not come in for the blood draw at visit 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Toll-like Receptor 4 GG Genotype</title>
          <description>Toll-like Receptor 4 (TLR4) -2026/GG gentoype hypothesized to be associated with less inflammation during Respiratory syncytial virus (RSV) infection</description>
        </group>
        <group group_id="B2">
          <title>Toll-like Receptor 4 AG/AA Genotypes</title>
          <description>Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during Respiratory syncytial virus (RSV) infection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.78" spread="0.56"/>
                    <measurement group_id="B2" value="0.82" spread="0.54"/>
                    <measurement group_id="B3" value="0.82" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nasal Interferon (IFN)-a2</title>
        <description>Interferon a2 was measured from nasal lavage samples by Luminex multiplex assay.</description>
        <time_frame>1-5 days during acute illness (not after day 5 of illness)</time_frame>
        <population>Analysis was per protocol based on the number of children enrolled by genotype and completed nasal washes at first visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Toll-like Receptor 4 GG Genotype</title>
            <description>Toll-like Receptor 4 (TLR4) -2026/GG gentoype hypothesized to be associated with less inflammation during Respiratory syncytial virus (RSV) infection</description>
          </group>
          <group group_id="O2">
            <title>Toll-like Receptor 4 AG/AA Genotypes</title>
            <description>Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during Respiratory syncytial virus (RSV) infection</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Interferon (IFN)-a2</title>
          <description>Interferon a2 was measured from nasal lavage samples by Luminex multiplex assay.</description>
          <population>Analysis was per protocol based on the number of children enrolled by genotype and completed nasal washes at first visit.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="3"/>
                    <measurement group_id="O2" value="26" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>A mixed random effects model was used both unadjusted and adjustment for relevant co-variates obtained from the literature.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Detected Nasal Interferon (IL)-2 Cytokine Expression</title>
        <description>IL-2 measured from nasal lavage samples by Luminex multiplex assay</description>
        <time_frame>1-5 days during acute illness (not after day 5 of illness)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Toll-like Receptor 4 GG Genotype</title>
            <description>Toll-like Receptor 4 (TLR4) -2026/GG gentoype hypothesized to be associated with less inflammation during Respiratory syncytial virus (RSV) infection</description>
          </group>
          <group group_id="O2">
            <title>Toll-like Receptor 4 AG/AA Genotypes</title>
            <description>Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during Respiratory syncytial virus (RSV) infection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Detected Nasal Interferon (IL)-2 Cytokine Expression</title>
          <description>IL-2 measured from nasal lavage samples by Luminex multiplex assay</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <p_value_desc>Analysis was per protocol based on the number of children enrolled by genotype and completed nasal washes at first visit.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>A mixed random effects model was used both unadjusted and adjustment for relevant co-variates obtained from the literature.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Toll-like Receptor 4 GG Genotype</title>
          <description>Toll-like Receptor 4 (TLR4) -2026/GG gentoype hypothesized to be associated with less inflammation during Respiratory syncytial virus (RSV) infection</description>
        </group>
        <group group_id="E2">
          <title>Toll-like Receptor 4 AG/AA Genotypes</title>
          <description>Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during Respiratory syncytial virus (RSV) infection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Subject withdraw before blood draw on second visit and small numbers recruited lead to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Theresa Guilbert, MD</name_or_title>
      <organization>University of Wisconsin-Madison</organization>
      <phone>608-263-9608</phone>
      <email>tguilbert@wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

